Cannabis Report
Home > Boards > US Listed > Medical - Drugs >

TrovaGene, Inc. (TROV)

Add TROV Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 7/13/2018 10:00:00 AM - Followers: 58 - Board type: Free - Posts Today: 0

Trovagene logoTrovagene, Inc. 
11055 Flintkote Ave., Suite B
San Diego, CA 92121
Tel: USA [+1] 858 217 4838
Fax: USA [+1] 858 217 4768 
TrovaGene, Inc. is a publicly traded company molecular diagnostics company, with headquarters in San Diego, California. We are dedicated to the development and commercialization of unique, proprietary, molecular in-vitro diagnostics technologies. 
The company's founding scientists were the first to report that cell free fragments of DNA from normal cell death that circulate in the blood can cross the kidney barrier and be detected in urine. 
These cell-free nucleic fragments that pass through the kidney ("transrenal" or Tr-DNA/RNA) can be used as genetic markers of disease. The company believes that this transrenal technology will open significant new markets in the molecular diagnostics field and lead to improvements in the area of personalized medicine.

TroveGene, Inc. news

Attention: Gabriele Cerrone, Director of Trovagene
Gabriele Cerrone, Founder and Chairman of FermaVir Pharmaceuticals.
FermaVir Pharmaceuticals was bought out by Inhibitex (INHX) in 2007 and Gabriele Cerrone was appointed a Director of the acquiring company.
Bristol-Myers Squibb offered $2.5 Billion to acquire Inhibitex.

Bristol-Myers Squibb to Acquire Inhibitex

InhibitexReleased: 01/07/12 09:13 PM EST
Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction, with an aggregate purchase price of approximately $2.5 billion, has been approved by the boards of directors of both companies. The board of directors of Inhibitex has agreed to recommend that Inhibitex's shareholders tender their shares in the tender offer. In addition, shareholders with beneficial ownership of approximately 17% of Inhibitex's common stock have entered into agreements with Bristol-Myers Squibb to support the transaction and to tender their shares in the tender offer.

Gabriele Cerrone holds an 11.4% interest in Trovagene.


Trovagene Closes Acquisition of CLIA Laboratory Assets
SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, today announced that it has closed its acquisition of MultiGEN Diagnostics, Inc.'s clinical laboratory assets.  Trovagene previously announced the execution of the Asset Acquisition Agreement on January 6, 2012.

Antonius Schuh, Ph.D. Joins TrovaGene, Inc. As Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)-- TrovaGene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, has announced that Antonius Schuh, Ph.D. has been named Chief Executive Officer. Dr. Schuh previously served as Chairman and Chief Executive Officer of Sorrento Therapeutics, Inc. (Pink Sheets: SRNE.PK), a biotechnology company he co-founded based on a proprietary platform to generate very large fully human antibody libraries. Sorrento Therapeutics merged in 2009 with a public company supported by Phillip Frost and the Frost Group.
Dr. Schuh also served as the founding CEO of AviaraDx, Inc., a leading molecular diagnostic innovator in oncology. In 2008, Dr. Schuh led the sale of AviaraDx to bioMerieux, which continues to operate AviaraDx under the name bioTheranostics. Before AviaraDx, Dr. Schuh served as CEO of Arcturus Bioscience, Inc., where he led the sale of Arcturus' life science business to Molecular Devices, Inc. From 2000 to 2005, Dr. Schuh served as the President and Chief Executive Officer of Sequenom, Inc. (Nasdaq: SQNM - News). He had joined Sequenom in 1996 as Managing Dierctor of its European operations, and led during his tenure, amongst others, the commercial launch of the MassARRA® system and numerous business development and corporate acquisition transactions. Dr. Schuh holds a degree in pharmaceutics and earned his Ph.D. in medicinal chemistry from the University of Bonn, Germany.
"We are pleased and fortunate that Dr. Schuh joins us to lead the transition of TrovaGene from a research stage organization to a commercial enterprise," states Dr. Thomas Adams, TrovaGene's Chairman. "The company has made significant efforts to establish the utility of trans-renal nucleic acids in urine as a diagnostic sample in clinical fields as diverse as detection of minimal residual disease in oncology, infectious disease, transplant medicine and prenatal monitoring. Dr. Schuh has a proven track record of building companies and creating value for shareholders. I look forward to working with him."
"I have observed TrovaGene closely over the past years, as I have been intrigued by the attractive opportunities the Company's proprietary trans-renal technologies offer, and I am confident that we can introduce novel diagnostic modalities with significant clinical utility based on this platform," states Dr. Schuh.

TROV executives
TROV board

Targeted $40 Billion market space:
TROV market space

Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TROV News: Current Report Filing (8-k) 07/10/2018 09:34:54 AM
TROV News: Trovagene Presents Outlook for Second Half of 2018 07/09/2018 08:00:00 AM
TROV News: Current Report Filing (8-k) 06/27/2018 11:34:37 AM
TROV News: Trovagene Announces Preliminary Clinical Data from First Dosing Cohort Demonstrating Durable Treatment Effect of PCM-075 in C... 06/27/2018 08:00:00 AM
TROV News: Current Report Filing (8-k) 06/22/2018 05:30:10 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1138   Looks bottomed to me - starter next week Klinsmann 07/13/18 10:00:00 AM
#1137   Sound good and I will go in with $Pistol Pete$ 07/12/18 04:22:28 PM
#1136   Same here my friend. Have several on watch. Klinsmann 07/12/18 04:21:58 PM
#1135   I want to see if this is something $Pistol Pete$ 07/12/18 04:20:02 PM
#1134   Good question. As always difficult to get reliable Klinsmann 07/12/18 04:19:08 PM
#1133   What is the outstanding shares here? $Pistol Pete$ 07/12/18 04:15:55 PM
#1132   On close watch, esp. after that "downward dance"... Klinsmann 07/09/18 09:01:51 AM
#1131   No cents watching this thing anymore, it had FloatinGator 07/02/18 10:34:40 AM
#1130   Lower than average volume and price almost hit stockmule 06/29/18 05:45:25 PM
#1129   Dead cat bounce, big pump coming or something stockmule 06/29/18 09:44:36 AM
#1128   Not yet. Big day coming soon GangstaKitty 06/28/18 11:08:15 PM
#1127   stick a fork in it FloatinGator 06/28/18 03:36:18 PM
#1126   They really kicked rocks on this one. The FloatinGator 06/27/18 03:44:29 PM
#1125   I am thinking BK at some point. No stockmule 06/26/18 06:40:23 PM
#1124   .80 bottom? Attila1905 06/26/18 01:00:54 PM
#1123   Probably just going to swim around here for FloatinGator 06/26/18 10:18:39 AM
#1122   Wow I didn't see that coming, lol. Bill stockmule 06/25/18 10:51:04 AM
#1121   The ceo resign and the director buying shares. MasterChi 06/22/18 11:29:11 PM
#1120   smelling like FREEF here, down again... FloatinGator 06/22/18 02:49:13 PM
#1119   Down day on positive news FloatinGator 06/21/18 12:36:15 PM
#1118   Depends on you definition of scam I guess. stockmule 06/20/18 09:49:56 AM
#1117   Can't wait until they give themselves options at stockmule 06/19/18 10:58:08 AM
#1116   Short interest only 28%, short volume means nothing, Full Contact Yoga 06/18/18 04:07:18 PM
#1115   Yeah man. I gotta grab a screenshot of FloatinGator 06/17/18 11:41:55 PM
#1114   Short Interest 106.89% highest I've ever seen and Zilla 06/17/18 07:43:24 PM
#1113   RSI 8.6 one of the lowest I have seen. FloatinGator 06/16/18 05:03:02 PM
#1112   It used to trade, aside from that, the Full Contact Yoga 06/14/18 07:44:58 AM
#1111   You use to be bullish on drug. Johnny_C 06/13/18 02:29:25 PM
#1110   they will max out the AS, continue dumping Full Contact Yoga 06/13/18 02:19:25 PM
#1109   Still. Very good volume and they sell out Johnny_C 06/13/18 02:14:49 PM
#1108   * * $TROV Video Chart 06-08-18 * * ClayTrader 06/08/18 04:06:28 PM
#1107   yes, and they've failed massively. they will Full Contact Yoga 06/08/18 10:44:49 AM
#1106   They are not the first to get funded Johnny_C 06/08/18 10:30:56 AM
#1105   Management, as always, truly screwed shareholders. I Full Contact Yoga 06/08/18 10:09:53 AM
#1104   Why is this a huge opp. Johnny_C 06/08/18 09:37:19 AM
#1103   Massive fail, proven scam, another RS guaranteed Full Contact Yoga 06/08/18 08:43:53 AM
#1102   offering 1$ 18 MIL SHARES jwest810 06/08/18 08:40:21 AM
#1101   nope, same lifetime failed scamming POS as always... Full Contact Yoga 06/08/18 08:14:45 AM
#1100   Has the management changed recently Johnny_C 06/07/18 05:12:37 PM
#1099   RS, followed by instant dilutive offering, some things Full Contact Yoga 06/04/18 11:53:35 PM
#1098   Totally surprised this didn't go that well, lol, stockmule 06/04/18 07:51:06 PM
#1097   Reverse is done and is 1 - 12 stockmule 06/04/18 09:40:39 AM
#1096   RS tomorrow, massive fail, exit if holding, play Full Contact Yoga 05/31/18 05:28:36 PM
#1095   They need a quorum, not the yes vote. Full Contact Yoga 05/29/18 02:50:09 PM
#1094   Apparently proposal in danger of failing if they're rcharlev 05/25/18 04:21:28 PM
#1093   Representatives from an investment firm representing TROV in rcharlev 05/25/18 04:15:13 PM
#1092   True. They could bust over $1 for 10 Full Contact Yoga 04/20/18 10:15:46 AM
#1091   If they had great news to put out stockmule 04/20/18 09:57:47 AM
#1090   They vote in May, can occur anytime after Full Contact Yoga 04/20/18 09:32:27 AM
#1089   When is the RS happening jwest810 04/19/18 01:11:55 PM